Manipal Health IPO Opens at ₹560–₹590 as Muted GMP Limits Listing Expectations

Manipal Health Enterprises opened its ₹9,275.22 crore initial public offering for subscription on Wednesday, July 29, 2026, giving investors an opportunity to participate in one of India’s largest hospital-network listings, although a muted grey-market premium and expensive valuation have reduced expectations of substantial listing-day gains. The IPO will remain open until July 31 and has been priced between ₹560 and ₹590 per equity share, with retail investors required to apply for at least one lot of 25 shares, involving a minimum investment of ₹14,750 at the upper end of the price band. The offering consists of a fresh issue of approximately 13.56 crore shares worth ₹8,000 crore and an offer for sale of around 2.16 crore shares valued at ₹1,275.22 crore by existing shareholders, including entities connected with Temasek, TPG, the Manipal group and other institutional investors. The company will not receive proceeds from the offer-for-sale portion, which will go to the selling shareholders after expenses and applicable taxes. According to the official offer documents, Manipal Health plans to use ₹5,552.76 crore from the fresh issue to repay or prepay borrowings and accumulated interest of its subsidiary, Manipal Hospitals Private Limited, while ₹574 crore will be used to acquire a minority stake in Sahyadri Hospitals and the remaining amount will support general corporate purposes. The planned debt reduction is one of the IPO’s strongest features because it could lower interest expenses, strengthen the balance sheet and allow a greater share of future operating cash flow to be used for hospital expansion and medical infrastructure. Manipal Health operates 49 hospitals, 21 clinics and 13,037 licensed beds across India and describes itself as the country’s largest pan-India multispecialty hospital network by bed capacity as of March 31, 2026. The group provides tertiary and quaternary treatment across areas such as cardiac sciences, oncology, neurosciences, gastroenterology, orthopaedics, renal sciences and organ transplantation and served approximately 7.63 million patients during FY26. Its revenue from operations increased from ₹8,242.25 crore in FY25 to ₹10,335.75 crore in FY26, while EBITDA rose from ₹2,261.02 crore to ₹2,721.87 crore, indicating strong business and operating growth. However, reported annual profit declined from ₹1,081.67 crore to approximately ₹916.52 crore, while total borrowings more than doubled to ₹10,553.43 crore, partly reflecting acquisitions and the expansion of the hospital network. Management plans to invest around ₹4,000 crore and add approximately 2,400 beds over the next three to four years, which could help the company benefit from rising healthcare demand, insurance penetration, an ageing population and growing demand for specialised medical treatment. Investors must nevertheless consider several risks, including the company’s relatively high dependence on Karnataka, which contributed 46.4% of FY26 operating revenue, the need to maintain hospital occupancy and doctor availability, integration challenges associated with acquisitions, regulatory action, medical-negligence claims and possible delays in receiving payments from insurers and government schemes. Valuation is another major concern, with one brokerage estimating that the IPO is priced at approximately 85.4 times FY26 earnings at the upper end, suggesting that a considerable portion of the company’s expected growth may already be reflected in the offer price. SBI Securities recommended subscribing based on Manipal Health’s scale, acquisition track record, planned capacity expansion and potential margin improvement after debt reduction, while Anand Rathi recommended the issue primarily for long-term investors. Arihant Capital and Angel One adopted a neutral position, arguing that the company’s strong fundamentals are balanced by its demanding valuation. Grey-market activity also indicated limited short-term excitement, with shares reportedly trading at a premium of approximately ₹8 over the upper issue price, suggesting a possible listing level near ₹598 if the unofficial trend were to continue. However, GMP is neither regulated nor guaranteed and can change sharply before listing. The share allotment is expected to be finalised on August 3, with a tentative listing on the BSE and NSE scheduled for August 5. Overall, Manipal Health enters the market with a nationally recognised hospital network, strong revenue growth, specialised healthcare capabilities and a clear plan to reduce debt, but its declining FY26 profit, acquisition-related risks and premium pricing mean that the offer may be more appropriate for investors with a long-term view of India’s healthcare sector than for applicants focused only on immediate listing gains.